After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new ...
Hims & Hers launches Labs, offering annual biomarker testing plans with doctor-developed guidance and expanded diagnostics planned across key health categories.
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is actively deepening its technology integration to transform how healthcare is delivered. The company recently appointed Mo ...
For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...
Zacks Investment Research on MSN
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 6 cents in third-quarter 2025, down 81.3% from the ...
Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...
President Donald Trump’s administration on Tuesday rolled out a memorandum aimed at limiting direct-to-consumer advertising for pharmaceuticals, with one senior administration official indicating that ...
Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 20 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback